#Lupus #SLE #Baricitinib #JAK #Autoimmunity
Systemic lupus erythematosus (SLE) is a
chronic
autoimmune disease characterized by the
aberrant production of autoantibodies
and
multisystem inflammation. Its clinical expression is heterogeneous and
unpredictable, with acute flares alternating with remission phases, making
management particularly complex. SLE predominantly affects women of
childbearing age, raising
specific issues related to fertility and obstetric
care.
Despite recent therapeutic advances, lupus
management still relies mainly on
conventional symptomatic treatments
(antimalarials, anti-inflammatory corticosteroids, immunosuppressants, etc.).
As a result, patients often exhibit
persistent disease activity despite
standard therapies, exposing them to an increased risk of irreversible damage
and significant morbidity.
Janus kinase (JAK) inhibitors, particularly
baricitinib, have caught the attention of the scientific community. By
targeting intracellular pathways involved in the signaling of multiple
pro-inflammatory cytokines,
baricitinib acts on both innate and adaptive
immunity. Several studies suggested a significant reduction in lupus activity
with a favorable safety profile. However, the two trials —
SLE-BRAVE-I and
SLE-BRAVE-II — yielded conflicting results, complicating the interpretation of
the treatment’s actual efficacy.
In this context, the present study was
initiated to assess the efficacy and safety of baricitinib in patients with
active lupus.
Targeted treatment or fancy placebo?
Combined data from
1,535 patients with active
lupus were analyzed. All were receiving
standardized background therapy and
were randomly assigned to one of three groups: baricitinib 4 mg, baricitinib 2
mg, or placebo. Treatment lasted for 52 weeks. The primary endpoint was the
proportion of patients achieving an SRI-4 response at the end of the study.
Overall results showed
no significant
difference between the baricitinib-treated groups and the placebo group (52% vs
46%, p > 0.05). However, notable benefits were observed in specific
subgroups:
- Among
patients receiving ≥10 mg/day of prednisone at baseline, response rates
were significantly higher in the baricitinib 4 mg (74%) and 2 mg (71%)
groups compared to placebo (p < 0.01);
- In highly
active patients (SLEDAI-2K ≥10), baricitinib 4 mg demonstrated enhanced
efficacy.
The
safety profile was generally similar across
groups. No major increase in serious adverse events was noted, except for a
slight uptick in herpes zoster infections in the baricitinib 4 mg group (5%).
Read next: Efficacy and safety of biotherapies in the treatment of systemic lupus erythematosus
A step toward precision
Systemic lupus erythematosus is a
chronic and
heterogeneous autoimmune disease that remains difficult to control long-term.
Despite available treatments, many patients experience
therapeutic failure or
require prolonged corticosteroid therapy, which is a
major source of
complications. One of the current challenges is
identifying targeted therapies
that can modulate inflammatory activity without increasing the medication
burden.
This study aimed to evaluate the efficacy and
safety of baricitinib, a JAK inhibitor, in patients with active lupus. The
results, combined with findings from the SLE-BRAVE-I and II trials, show that
baricitinib
does not significantly reduce lupus activity across the entire
studied population. However, efficacy signals were observed in certain
subgroups, especially in highly active patients or those on high-dose
corticosteroids at baseline. Moreover, the treatment’s safety profile remains
generally satisfactory and aligns with other known indications for the drug.
Additional studies are needed to
confirm
baricitinib’s relevance in well-defined subgroups of lupus patients. The
observed efficacy in certain clinical profiles, particularly in highly active
or heavily treated patients, suggests a potential for
targeted therapeutic use
that warrants further exploration. To achieve this, it is essential to identify
predictive biomarkers of response to
better select patients likely to benefit
from the treatment.
Simultaneously,
adjusting evaluation
criteria—often insufficiently sensitive to clinically relevant
variations—emerges as a key methodological lever. The design of future clinical
trials should rely on more refined recruitment strategies, focused on homogeneous
clinical phenotypes and integrating biological, immunological, and
pharmacogenetic parameters. These advances would support the emergence of a
more stratified and personalized therapeutic approach to lupus, overcoming the
limitations of current treatments and addressing each patient’s specific needs.
Read next: Between cholesterol and systemic lupus erythematosus
